SURPASS-2: tirzepatide vs. semaglutide head-to-head

SURPASS-2 is the Phase 3 trial published in the New England Journal of Medicine in 2021 that directly compared tirzepatide and semaglutide in adults with type-2 diabetes. The trial matters for research design because it's one of the few head-to-head incretin comparisons in the literature — and it cleanly answers the question "does dual GIP/GLP-1 agonism actually outperform single GLP-1 agonism, or is it just a marketing claim?"

Trial design

1,879 adults with T2D, randomized 1:1:1:1 to:

• Tirzepatide 5 mg weekly SC
• Tirzepatide 10 mg weekly SC
• Tirzepatide 15 mg weekly SC
• Semaglutide 1 mg weekly SC (the maximum approved diabetes dose at trial start)

Primary outcome: change in HbA1c at 40 weeks. Secondary: body weight change, proportion reaching HbA1c < 7%, glycemic excursions, lipid panel.

Headline findings

All three tirzepatide doses showed greater HbA1c reduction than semaglutide 1 mg, with statistical significance. The weight-loss gap was larger: tirzepatide 15 mg achieved nearly double the weight reduction of semaglutide at the maximum diabetes dose.

What it tells us about dual agonism

The interesting science is in the dose-response. At matched doses (5 mg tirzepatide vs. 1 mg semaglutide — both at the lower end of their respective ranges), tirzepatide produced 33% greater weight reduction. This implies that activating GIP receptors in addition to GLP-1 receptors adds a measurable, separable effect — not just "more drug" but a qualitatively different signal.

For research designs that want to isolate GLP-1 effects specifically, semaglutide is the appropriate tool. For research that needs the broader incretin signal (or wants to study the GIP contribution), tirzepatide gives you both receptors. SURPASS-2 quantifies the practical difference between the two.

Adverse events

GI events were the dominant tolerability signal in both compounds. Nausea, diarrhea, vomiting were each in the 17–25% range for tirzepatide arms, and 18–24% for semaglutide — broadly comparable. Hypoglycemia was rare in both (these are glucose-dependent secretagogues), which is methodologically important: research models comparing incretin compounds against insulin-based interventions should expect very different hypoglycemia profiles.

What the trial doesn't tell you

SURPASS-2 used semaglutide 1 mg, which was the maximum diabetes-indicated dose at the time. Higher semaglutide doses (2.4 mg, the Wegovy obesity dose) were not in this comparison. So the trial cleanly answers "tirzepatide vs. semaglutide-at-T2D-dose" but does not answer "tirzepatide vs. semaglutide-at-obesity-dose." A later head-to-head (SURMOUNT-5) addresses that question for obesity research; check the published literature for findings.

Notes

This is a research summary of published clinical data. It is not a recommendation for any specific research protocol or design. For research use only.

Reference

1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM 2021;385:503–515. PMID: 34170647